Corcept Therapeutics Incorporated (CORT) Income Statement

The sequential acceleration from 2026Q1's 4.9% to 31.7% in 2026Q2 suggests a re-acceleration in patient demand or inventory dynamics, though the underlying driver warrants scrutiny. Given the single-product focus on Korlym, this volatility may reflect lumpy specialty pharmacy ordering rather than a durable trend. Investors should monitor whether this growth rate is sustainable as the company approaches the relacorilant transition.

The near-100% gross margin underscores the negligible cost of goods for an orphan drug, but the operating margin compression to 16.1% from 25.5% in 2024Q3 reflects aggressive R&D and SG&A spending. This suggests management is deliberately sacrificing near-term profitability to fund the relacorilant Phase 3 program and legal defenses. The margin structure appears stable at the gross level, but operating leverage is currently negative as expenses outpace revenue growth.

The 2026Q1 operating loss was driven by a spike in R&D to $66.3M and SG&A to $145.4M, which together exceeded gross profit. While 2026Q2 recovered, the trend shows that operating income is not scaling with revenue due to heavy investment. This implies that the company is in a reinvestment phase, and operating leverage will only materialize if revenue growth continues without proportional expense increases.

The rapid growth in SG&A likely reflects heightened legal expenses from the Teva litigation and expansion of the specialty sales force to support relacorilant's launch preparation. R&D spending has also remained elevated, averaging over $60M per quarter, indicating a deliberate shift toward pipeline advancement. This cost structure suggests that the company is prioritizing long-term franchise durability over short-term profitability, which may pressure margins until new revenue streams materialize.